Corvus Pharmaceuticals Reports Q3 GAAP EPS Miss Amid Significant Cash Increase
Corvus Pharmaceuticals (CRVS) reported third-quarter GAAP earnings per share of -$0.22, missing analyst expectations by $0.02. Despite the earnings miss, the company demonstrated a substantial strengthening of its liquidity position. As of September 30, 2026, Corvus held $202.9 million in cash, cash equivalents, and marketable securities. This represents a significant increase from the $56.8 million reported as of December 31, 2025, providing the company with a larger capital cushion for ongoing operations.
Tickers: $CRVS
Topics: cash position earnings miss financial results
Read the full article at Seeking Alpha
Part of the story Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates (8 articles)